Literature DB >> 3665338

Disposition kinetics of moclobemide, a monoamine oxidase-A enzyme inhibitor: single and multiple dosing in normal subjects.

M P Schoerlin1, M Mayersohn, A Korn, H Eggers.   

Abstract

The absorption and disposition kinetics of moclobemide (Ro 11-1163), a new reversible and preferential monoamine oxidase-A enzyme inhibitor, were examined in 12 normal male subjects. An intravenous infusion was administered before and after a 15-day multiple oral dosing regimen (100 mg t.i.d.). Plasma concentration-time data were obtained after each intravenous infusion, after the first oral dose, during two dosing intervals at steady state, and before the second daily dose on several days. The disposition values (percent coefficient of variation in parentheses) after the first and second intravenous infusions, respectively, were: clearance, 39.4 (15%) and 29.1 (12%) L/hr; elimination half-life, 1.60 (15%) and 2.00 (18%) hours; and volume of distribution at steady state, 84.3 (11%) and 80.7 (15%) L. The absolute oral bioavailability increased from 0.56 after the first oral dose to 0.86 and 0.90 after the first and second weeks of administration, respectively. The reduced metabolic, presumably hepatic, clearance may be the result of self-inhibition or metabolite inhibition of moclobemide clearance.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3665338     DOI: 10.1038/clpt.1987.169

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  11 in total

Review 1.  Interactions of moclobemide with concomitantly administered medication: evidence from pharmacological and clinical studies.

Authors:  R Amrein; T W Güntert; J Dingemanse; T Lorscheid; M Stabl; W Schmid-Burgk
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

Review 2.  Metabolism of the newer antidepressants. An overview of the pharmacological and pharmacokinetic implications.

Authors:  S Caccia
Journal:  Clin Pharmacokinet       Date:  1998-04       Impact factor: 6.447

Review 3.  The Role of Metabolites of Antidepressants in the Treatment of Depression.

Authors:  M V Rudorfer; W Z Potter
Journal:  CNS Drugs       Date:  1997-04       Impact factor: 5.749

Review 4.  Antidepressants. A comparative review of the clinical pharmacology and therapeutic use of the 'newer' versus the 'older' drugs.

Authors:  M V Rudorfer; W Z Potter
Journal:  Drugs       Date:  1989-05       Impact factor: 9.546

5.  Moclobemide excretion in human breast milk.

Authors:  G Pons; M P Schoerlin; Y K Tam; C Moran; J P Pfefen; C Francoual; A M Pedarriosse; J Chavinie; G Olive
Journal:  Br J Clin Pharmacol       Date:  1990-01       Impact factor: 4.335

6.  Moclobemide poisoning: toxicokinetics and occurrence of serotonin toxicity.

Authors:  Geoffrey K Isbister; L P Hackett; Andrew H Dawson; Ian M Whyte; Anthony J Smith
Journal:  Br J Clin Pharmacol       Date:  2003-10       Impact factor: 4.335

Review 7.  Clinical pharmacokinetics of the monoamine oxidase-A inhibitor moclobemide.

Authors:  M Mayersohn; T W Guentert
Journal:  Clin Pharmacokinet       Date:  1995-11       Impact factor: 6.447

Review 8.  Pharmacokinetic optimisation of therapy with newer antidepressants.

Authors:  P J Goodnick
Journal:  Clin Pharmacokinet       Date:  1994-10       Impact factor: 6.447

9.  Monoamine oxidase-A: pharmacodynamics in humans of moclobemide, a reversible and selective inhibitor.

Authors:  N H Holford; T W Guentert; J Dingemanse; L Banken
Journal:  Br J Clin Pharmacol       Date:  1994-05       Impact factor: 4.335

Review 10.  Biochemistry and pharmacology of reversible inhibitors of MAO-A agents: focus on moclobemide.

Authors:  N P Nair; S K Ahmed; N M Kin
Journal:  J Psychiatry Neurosci       Date:  1993-11       Impact factor: 6.186

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.